The prospective use of COX-2 inhibitors for the treatment of temporomandibular joint inflammatory disorders

International Journal of Immunopathology and Pharmacology

Volumn 16, Issue 2 SUPPL., 2003, Pages 1-9

  Kerins, C A ^a   Spears, R ^a   Bellinger, L L ^a   Hutchins, Bob ^a,b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b BAYLOR COLLEGE OF DENTISTRY   (United States)

Author keywords

COX 2 inhibitors; Cyclooxygenase; Inflammation; NSAIDS; TMJ

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; FREUND ADJUVANT; HISTAMINE; IBUPROFEN; ICOSANOID; INTERLEUKIN 1BETA; PROSTAGLANDIN E2; ROFECOXIB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANKLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM ULCER; DRUG DESIGN; DRUG SELECTIVITY; EATING; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HAND; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INHIBITION KINETICS; INTERPERSONAL COMMUNICATION; KNEE; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; TEMPOROMANDIBULAR JOINT DISORDER; THROMBOCYTE DYSFUNCTION;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; TEMPOROMANDIBULAR JOINT; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 0142121515     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Hinton R.J. and D.S. Carlson. 1997. Effect of function on growth and remodeling of the temporomandibular joint. In Science and Practice of Occlusion. C.McNeill, ed. Quintessence Publishing Co. Inc. Chicago, p. 95.
2. Scapino R.P. 1997. Morphology and mechanism of the jaw joint. In Science and Practice of Occlusion. C.McNeill, ed. Quintessence Publishing Co. Inc. Chicago, p. 23.
3. Uddman R., T. Grunditz, J. Kato and F. Sundler. 1998. Distribution and origin of nerve fibers in the rat temporomandibular joint capsule. Anat. Embryol. 197:273.
4. Dreessen D., Z. Halata and T. Strasmann. 1990. Sensory innervation of the temporomandibular joint in the mouse. Acta Anat. 139:154.
5. Morani V., V. Previgliano, G.M. Schierano and G. Ramieri. 1994. Innervation of the human temporomandibular joint capsule and disc as revealed by immunohistochemistry for neurospecific markers. J. Orofac. Pain 8:36.
6. Shimizu S., M.A. Kido, T. Kiyoshima and T. Tanaka. 1996. Postnatal development of protein gene product 9.5- and calcitonin gene-related peptide-like immunoreactive nerve fibers in the rat temporomandibular joint. Anat. Rec. 245:568.
7. Kido M.A., T. Kondo, N. Ayasaka, Y. Terada and T. Tanaka. 1991. The peripheral distribution of trigeminal nerve fibres in the rat temporomandibular joint studied by an anterograde axonal transport method with wheat germ agglutinin-horseradish peroxidase. Arch. Oral Biol. 36:397.
8. Carlson D.S. 1994: Growth of the temporomandibular joint. In Temporomandibular Joint and Masticatory Muscle Disorders. G.A. Zarb, G.E. Carlsson, B.J. Sessle, and N.D. Mohl eds. Munksgaard Copenhagen, p. 128.
9. Fuentes M.A., L.A. Opperman, L.L. Bellinger, D.S. Carlson and R.J. Hinton. 2002. Regulation of cell proliferation in rat mandibular condylar cartilage in explant culture by insulin-like growth factor-1 and fibroblast growth factor-2. Arch. Oral Biol. 47:643.
10. Shibata S., K. Fukada, S. Suzuki, T. Ogawa and Y. Yamashita. 2002. In situ hybridization and immunohistochemistry of bone sialoprotein and secreted phosphoprotein 1 (osteopontin) in the developing mouse mandibular condylar cartilage compared with limb bud cartilage. J Anat. 200:309.
11. Visnapuu V., T. Peltomaki, O. Ronning and S. Syrjanen. 2002. Distribution of insulin-like growth factor-I mRNA in the mandibular condyle and rib cartilage of the rat during growth. Arch. Oral Biol. 47:791.
12. Ronning O. 1991. Cartilage, function and craniofacial morphogenesis. Proc. Finn. Dent. Soc. 87:231.
13. Mizoguchi I., M. Nakamura, I. Takahashi, Y. Sasano, M. Kagayama and H. Mitani. 1993. Presence of chondroid bone on rat mandibular condylar cartilage. An immunohistochemical study. Anat. Embryol. 187:9.
14. Ng M.C., R.P. Harper, C.T. Le and B.S. Wong. 1999. Effects of estrogen on the condylar cartilage of the rat mandible in organ culture. J. Oral Maxillofac. Surg. 57:818.
15. Cohen M.M., Jr. 2000. Merging the old skeletal biology with the new. 1. Intramembranous ossification, endochondral ossification, ectopic bone, secondary cartilage, and pathologic considerations. J. Craniofac. Genet. Dev. Biol. 20:84.
16. Howell D.S. 2002. Articular cartilage calcification and matrix vesicles. Curr. Rheumatol. Rep. 4:265.
17. Kido M.A., T. Kiyoshima, T. Kondo, N. Ayasaka, R. Moroi, Y. Terada and T. Tanaka. 1993. Distribution of substance P and calcitonin gene-related peptide-like immunoreactive nerve fibers in the rat temporomandibular joint. J. Dent. Res. 72:592.
18. Carleson J., I. Bileviciute, E. Theodorsson, B. Appelgren, A. Appelgren, N. Yousef, S. Kopp and T. Lundeberg. 1997. Effects of adjuvant on neuropeptide-like immunoreactivity in the temporomandibular joint and trigeminal ganglia. J. Orofac. Pain 11:195.
19. Appelgren A., B. Appelgren, S. Eriksson, S. Kopp, T. Lundeberg, M. Nylander and E. Theodorsson. 1991. Neuropeptides in temporomandibular joints with rheumatoid arthritis: a clinical study. Scand. J. Dent. Res. 99:519.
20. Hutchins B., R. Spears, R.J. Hinton and R.P. Harper. 2000. Calcitonin gene-related peptide and substance P immunoreactivity in rat trigeminal ganglia and brainstem following adjuvant-induced inflammation of the temporomandibular joint. Arch. Oral Biol. 2000. 45:335.
21. Spears R., B. Hutchins and R.J. Hinton. 1998. Capsaicin application to the temporomandibular joint alters calcitonin gene-related peptide levels in the trigeminal ganglion of the rat. J. Orofac. Pain 12:108.
22. Alstergren P., A. Appelgren, B. Appelgren, S. Kopp, T. Lundeberg and E. Theodorsson. 1995. Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis. Arch. Oral Biol. 40:127.
23. Appelgren A., B. Appelgren, S. Kopp, T. Lundeberg and E. Theodorsson. 1995. Neuropeptides in the arthritic TMJ and symptoms and signs from the stomatognathic system with special consideration to rheumatoid arthritis. J. Orofac. Pain 9:215.
24. Appelgren A., B. Appelgren, S. Kopp, T. Lundeberg and E. Theodorsson. 1998. Substance P-associated increase of intra-articular temperature and pain threshold in the arthritic TMJ. J. Orofac. Pain 12:101.
25. Kopp S. 1998. The influence of neuropeptides, serotonin, and interleukin 1 beta on temporomandibular joint pain and inflammation. J. Oral Maxillofac. Surg. 56:189.
26. Nordahl S., P. Alstergren and S. Kopp. 2000. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J. Oral Maxillofac. Surg. 58:525.
27. Takahashi O., R.J. Traub and M.A. Ruda. 1988. Demonstration of calcitonin gene-related peptide immunoreactive axons contacting dynorphin A(1-8) immunoreactive spinal neurons in a rat model of peripheral inflammation and hyperalgesia. Brain Res. 475:168.
28. LeResche L. 1997. Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev. Oral Biol. Med 8:291.
29. Kapila S. and Y. Xie. 1998. Targeted induction of collagenase and stromelysin by relaxin in unprimed and beta-estradiol-primed diarthrodial joint fibrocartilaginous cells but not in synoviocytes. Lab. Invest. 78:925.
30. Bell W.E. 1960. Temporomandibular joint desease. Egan Company, Dallas.
31. Merskey H. 1986. Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms. Pain 3(S):1.
32. Dworkin S.F. and L. LeResche. 1992. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. J. Craniomandib. Disord. 6:301.
33. Kaneyama K., N. Segami, M. Nishimura, T. Suzuki and J. Sato. 2002. Importance of proinflammatory cytokines in synovial fluid from 121 joints with temporomandibular disorders. Brit. J. Oral Maxillofacial Surg. 40:418.
34. Carlsson G.E., I. Egermark and T. Magnusson. 2002. Predictors of signs and symptoms of temporomandibular disorders: a 20-year follow-up study from childhood to adulthood. Acta Odontol. Scand. 60:180.
35. Holmlund A.B. and S. Axelsson. 1996. Temporomandibular arthropathy: correlation between clinical signs and symptoms and arthroscopic findings. Int. J. Oral Maxillofac. Surg. 25:178.
36. Lund J.P., C.G. Widmer and J.S. Feine. 1995. Validity of diagnostic and monitoring tests used for temporomandibular disorders. J. Dent. Res. 74:1133.
37. McNeill C. 1997. Management of temporomandibular disorders: Concepts and controversies. J. Prosthet. Dent. 77:510.
38. Turp J.C., C.J. Kowalski and C.S. Stohler. 1998. Treatment-seeking patterns of facial pain patients: many possibilities, limited satisfaction. J. Orofac. Pain 12:61.
39. Fricton J.R., J.O. Look, E. Schiffman and J. Swift. 2002. Long-term study of temporomandibular joint surgery with alloplastic implants compared with nonimplant surgery and nonsurgical rehabilitation for painful temporomandibular joint disc displacement. J. Oral Maxillofac. Surg. 60:1400.
40. Hla T. and K. Neilson. 1992. Human Cyclooxygenase-2 cDNA. PNAS 89:7384.
41. Blanco F.J., R. Guitian, J. Moreno, F.J. de Toro and F. Galdo. 1999. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J. Rheumatol. 26:1366.
42. Goldenberg M.M. 1999. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin. Ther. 21:1497.
43. Seibert K., Y. Zhang, K. Leahy, S. Hauser, J. Masferrer, W. Perkins, L. Lee and P. Isakson. 1994. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 91:12013.
44. Gierse J.K., C.M. Koboldt, M.C. Walker, K. Seibert and P.C. Isakson. 1999. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 339:607.
45. Copeland R.A., J.M. Williams, J. Giannaras, S. Nurnberg, M. Covington, D. Pinto, S. Pick and J.M. Trzaskos. 1994. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA 91:11202.
46. Hochberg M.C. 2002. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin. Arthritis Rheum. 32:4.
47. Garner S., D. Fidan, R. Frankish, M. Judd, B. Shea, T. Towheed, G. Wells and P. Tugwell. 2002. Celecoxib for rheumatoid arthritis. Cochrane. Database. Syst. Rev. CD003831.
48. Schnitzer T.J., K. Truitt, R. Fleischmann, P. Dalgin, J. Block, Q. Zeng, J. Bolognese, B. Seidenberg and E.W. Ehrich. 1999. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase 11 Rofecoxib Rheumatoid Arthritis Study Group. Clin. Ther. 21:1688.
49. Gynther G.W., A.B. Holmlund, F.P. Reinholt and S. Lindblad. 1997. Temporomandibular joint involvement in generalized osteoarthritis and rheumatoid arthritis: a clinical, arthroscopic, histologic, and immunohistochemical study. Int. J. Oral Maxillofac. Surg. 26:10.
50. Chenitz J.E. 1992. Rheumatoid arthritis and its implications in temporomandibular disorders. Cranio 10:59.
51. Bayar N., S.A. Kara, I. Keles, M.C. Koc, D. Altinok and S. Orkun. 2002. Temporomandibular joint involvement in rheumatoid arthritis: a radiological and clinical study. Cranio 20:105.
52. Quinn J.H. and N.G. Bazan. 1990. Identification of prostaglandin E2 and leukotriene B4 in the synovial fluid of painful, dysfunctional temporomandibular joints. J. Oral Maxillofac. Surg. 48:968.
53. Quinn J.H., J.N. Kent, A. Moise and W.J. Lukiw. 2000. Cyclooxygenase-2 in synovial tissue and fluid of dysfunctional temporomandibular joints with internal derangement. J. Oral Maxillofac. Surg. 58:1229.
54. Kang R.Y., J. Freire-Moar, E. Sigal and C.Q. Chu. 1996. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br. J. Rheumatol. 35:711.
55. Yoshida H., Y. Fukumura, S. Fujita, M. Nishida and T. Iizuka. 2002. The expression of cyclooxygenase-2 in human temporomandibular joint samples: an immunohistochemical study. J. Oral Rehabil. 29:1146.
56. Alstergren P. and S.Kopp. 2000. Prostaglandin E2 in temporomandibular joint synovial fluid and its relation to pain and inflammatory disorders. J. Oral Maxillofac. Surg. 58:180.
57. Murakami K.I., T. Shibata, E. Kubota and H. Maeda. 1998. Intra-articular levels of prostaglandin E2, hyaluronic acid, and chondroitin-4 and -6 sulfates in the temporomandibular joint synovial fluid of patients with internal derangement. J. Oral Maxillofac. Surg. 56:199.
58. Ren K. and R. Dubner. 1999. Inflammatory Models of Pain and Hyperalgesia. ILAR. J. 40:111.
59. Imbe H., K. Iwata, Q.Q. Zhou, S. Zou, R. Dubner and K. Ren. 2001. Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation. Implications for persistent temporomandibular pain. Cells Tissues, Organs 169:238.
60. Calvino B., M.O. Crepon-Bernard and D. Le Bars. 1987. Parallel and behavioural studies of adjuvant-induced arthritis in the rat: possible relationship with 'chronic pain'. Behav. Brain Res. 24:11.
61. Donaldson L.F., J.R. Seckl and D.S. McQueen. 1993. A discrete adjuvant-induced monoarthritis in the rat: effects of adjuvant dose. J. Neurosci. Methods 49:5.
62. Kleinau S., H. Erlandsson and L. Klareskog. 1994. Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin. Exp. Immunol. 96:281.
63. Harper R.P., C.A. Kerins, R. Talwar, R. Spears, B. Hutchins, D.S. Carlson, J.E. McIntosh, and L.L. Bellinger. 2000. Meal pattern analysis in response to temporomandibular joint inflammation in the rat. J. Dent. Res. 79:1704.
64. Kerins C. A., D. S. Carlson, J. E. McIntosh and L.L. Bellinger. 2003. Meal pattern changes associated with temporomandibular joint inflammation/pain in rats; analgesic effcts. Pharmacol. Biochem. Behav. (In Press).
65. Woolf C.J. and T.P. Doubell. 1994. The pathophysiology of chronic pain-increased sensitivity to low threshold A beta-fibre inputs. Curr. Opin. Neurobiol. 4:525.
66. Abbadie C., J.L. Brown, P.W. Mantyh and A.I. Basbaum. 1996. Spinal cord substance P receptor immunoreactivity increases in both inflammatory and nerve injury models of persistent pain. Neuroscience 70:201.
67. Urban M.O. and G.F. Gebhart. 1999. Central mechanisms in pain. Med. Clin. North Am. 83:585.
68. Iwata K., A. Tashiro, Y. Tsuboi, T. Imai, R. Sumino, T. Morimoto, R. Dubner and K. Ren. 1999. Medullary dorsal horn neuronal activity in rats with persistent temporomandibular joint and perioral inflammation. J. Neurophysiol. 82:1244.
69. Hutchins B., H. Patel and R. Spears. 2002. Attenuation of pro-inflammatory neuropeptide levels produced by a cyclooxygenase-2 inhibitor in an animal model of chronic temporomandibular joint inflammation. J. Orofac. Pain 16:312.
70. Simon L.S., J.S. Smolen, S.B. Abramson, G. Appel, C. Bombardier, D.C. Brater, F.C. Breedveld, K. Brune, G.R. Burmester, L.J. Crofford, M. Dougados, R.N. DuBois, G.A. Fitzgerald, W. Frishman, L.A. Garcia Rodriguez, M.C. Hochberg, J.R. Kalden, L. Laine, M.J. Langman, S.M. Prescott, L.B. van de Putte, A. Whelton, W.B. White and G.H. Willaims. 2002. Controversies in COX-2 selective inhibition. J. Rheumatol. 29:1501.
71. Bingham C.O., III. 2002. Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Cleve. Clin. J. Med. 69:S15.
72. McMurray R.W. and K.J. Hardy. 2002. Cox-2 inhibitors: today and tomorrow. Am. J. Med. Sci. 323:181.
73. Crofford L.J. 2003. COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease. Arthritis Res. Ther. 5:25.
74. Stichtenoth D.O. and J.C. Frolich. 2003. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 63:33.
75. Flower R.J. 2003. The development of COX2 inhibitors. Nat. Rev. Drug Discov. 2:179.
76. Chandrasekharan N.V., H. Dai, K.L. Roos, N.K. Evanson, J. Tomsik, T.S. Elton and D.L. Simmons. 2002. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 99:13926.
77. Willoughby D.A., A.R. Moore and P.R. Colville-Nash. 2000. COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease. Lancet 355:646.
78. Botting R.M. 2000. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin. Infect. Dis. 31 (S5):S202.
79. Moore B.C. and D.L. Simmons. 2000. COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. Curr. Med. Chem. 7:1131.
80. Simmons D.L., D. Wagner and K. Westover. 2000. Nonsteroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever. Clin. Infect. Dis. 31 (85):S211.